
Dry Powder Inhaler Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Description
Dry Powder Inhaler Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Summary
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
The Dry Powder Inhaler Devices report provides key information and data related to:
Extensive coverage of the Dry Powder Inhaler Devices under development
Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths, and estimated approval dates
Reviews of major players involved in the pipeline product development.
Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and the number of trials of the major Dry Powder Inhaler Devices pipeline products.
Review of Recent Developments in the segment / industry
The Dry Powder Inhaler Devices report enables you to:
Access significant competitor information, analysis, and insights to improve your R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
Formulate market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
The GlobalData Differentiation
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:
- 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
- 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports
- 64,000+ medical equipment company profiles
- 5,600+ company profiles of medical equipment manufacturers in China and India
- 2,200+ company profiles of medical equipment manufacturers in Japan
- 1,200+ companies’ revenue splits and market shares
- 1,600+ quarterly and annual medical equipment company financials
- 850+ medical equipment company SWOTs
- 28,000+ pipeline product profiles
- 56,400+ marketed product profiles
- 47,000+ clinical trials
- 41,500+ trial investigators
- 7,000+ reports on companies with products in development
- 44,000+ deals in the medical equipment industry
- 1,100+ surgical and diagnostic procedures by therapy area
- 50+ key healthcare indicators by country
- 431,000+ Themes Content Items
- 600+ Influencers
- 1,900+ Analysts & Researchers
- 0.5m+ Community Members
- 141,000+ Macroeconomic Indicators
- 1,013,000+ City Indicators
- Extensive coverage of the Dry Powder Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
126 Pages
- About GlobalData
- Dry Powder Inhaler Devices Overview
- Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
- Dry Powder Inhaler Devices - Pipeline Products by Territory
- Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
- Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
- Dry Powder Inhaler Devices - Ongoing Clinical Trials
- Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
- Dry Powder Inhaler Devices - Companies Pipeline Products by Stage of Development
- Acorda Therapeutics Inc Company Overview
- Advent Pharmaceuticals Pty Ltd Company Overview
- Aespira Ltd. Company Overview
- AKELA Pharma Inc. (Inactive) Company Overview
- Bayer AG Company Overview
- Cambridge Healthcare Innovations Ltd Company Overview
- Creare LLC Company Overview
- DMK Pharmaceuticals Corp Company Overview
- Eli Lilly and Co Company Overview
- Glenmark Pharmaceuticals Ltd Company Overview
- GSK plc Company Overview
- Hovione Technology Ltd Company Overview
- Iconovo AB Company Overview
- Lupin Pharmaceuticals Inc Company Overview
- MannKind Corp Company Overview
- Monash University Company Overview
- Nektar Therapeutics Company Overview
- Ology Bioservices Inc Company Overview
- OPKO Health Inc Company Overview
- OtiTopic Inc Company Overview
- Phargentis SA Company Overview
- Pharmaxis Ltd Company Overview
- PureIMS BV Company Overview
- Quench Medical Inc Company Overview
- Respira Therapeutics Inc Company Overview
- Respirent Pharmaceuticals Co Ltd Company Overview
- Sandoz International GmbH Company Overview
- Sheffield Hallam University Company Overview
- Shin Nippon Biomedical Laboratories Ltd Company Overview
- Spyryx Biosciences Inc (Inactive) Company Overview
- Teva Pharmaceutical Industries Ltd Company Overview
- Transpire Bio Inc Company Overview
- University of Kansas Company Overview
- University of Sydney Company Overview
- University of Texas Medical Branch at Galveston Company Overview
- Vectura Group Plc Company Overview
- Verona Pharma Plc Company Overview
- Virginia Commonwealth University Company Overview
- Oct 30, 2023: Chiesi Announces New Senior Level Changes to Leadership Team
- Oct 24, 2023: 3M Reports Third Quarter 2023 Results; Company Increases Full Year Adjusted Earnings and Cash Flow Expectations
- Oct 19, 2023: DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
- Oct 16, 2023: Orion publishes Interim Report for January-September 2023 on Thursday 26 October 2023
- Sep 28, 2023: Teva Announces Changes to Executive Management Team
- Sep 05, 2023: MannKind Announces Participation at Upcoming Conferences
- Aug 28, 2023: Novartis to Let Go 100 Employees in Latest Round of Layoffs
- Aug 23, 2023: 3M Appoints Carrie Cox as Chairman of the Board of Directors of the Independent Health Care Company
- Aug 22, 2023: Bryan Hanson Named CEO of 3M's Health Care Business Group
- Aug 17, 2023: Ziccum to present at Investor Conference BioFuture 2023 in New York
- Aug 01, 2023: MannKind Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
- Jul 31, 2023: MannKind to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
- Jul 07, 2023: Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
- Jul 05, 2023: Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2
- Jul 04, 2023: Orion Publishes Half-year Financial Report for January - June 2023
- Jun 02, 2023: Ziccum appoints senior biopharma executive as new CFO
- May 24, 2023: Ziccum: Bulletin from the Annual General Meeting
- May 24, 2023: Dr. Burkhard Blank joins MannKind as executive vice president of research & development and chief medical officer
- May 15, 2023: Adamis Pharmaceuticals reports Q1 2023 financial results and provides corporate update
- May 09, 2023: 3M annual meeting highlights business portfolio, innovation, and actions to drive future performance
- May 09, 2023: Mannkind reports 2023 first quarter financial results
- May 08, 2023: Adamis Pharmaceuticals schedules Q1 2023 financial results conference call and corporate update
- May 03, 2023: Hovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery
- May 02, 2023: MannKind Corp. to hold 2023 first quarter financial results conference call on May 9, 2023
- Apr 28, 2023: Iconovo Publishes Annual Report for 2022
- Apr 28, 2023: Iconovo Announces Interim Report January - March 2023
- Apr 26, 2023: Ziccum announces releases of interim report Q1 2023
- Apr 25, 2023: OPKO Health to report Q1 2023 financial results on May 3, 2023
- Apr 25, 2023: 3M announces more layoffs
- Apr 20, 2023: Iconovo announces notice to the annual general meeting
- Apr 13, 2023: Orion publishes Interim Report for January-March 2023 on Thursday 27 April 2023
- Apr 04, 2023: PureIMS secures funding to develop inhalation product
- Mar 27, 2023: Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
- Mar 14, 2023: Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
- Mar 10, 2023: GSK publishes Annual Report 2022
- Feb 28, 2023: Orion Group Announces Financial Statement documents 2022, Corporate Governance Statement and Remuneration Report published
- Feb 23, 2023: MannKind Corp. Reports 2022 Fourth Quarter and Full Year Financial Results
- Feb 17, 2023: ZICCUM releases Annual Report 2022
- Feb 16, 2023: OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
- Feb 16, 2023: MannKind Corp. to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
- Feb 09, 2023: Orion Group Announces Financial Statement Release 2022
- Feb 08, 2023: Iconovo Announces Financial Statement 1 January to 31 December 2022
- Feb 01, 2023: Novartis Announces Annual Report 2022
- Jan 30, 2023: Chiesi appoints Giuseppe Accogli as new Group CEO
- Jan 26, 2023: Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023
- Jan 24, 2023: 3M Reports Fourth-Quarter and Full-Year 2022 Results
- Jan 24, 2023: 3M Lays off 2500 employees
- Jan 12, 2023: Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
- Dec 15, 2022: Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer
- Nov 21, 2022: Teva Announces Appointment of Richard Francis as President and CEO
- Nov 21, 2022: Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO
- Nov 16, 2022: Iconovo appoints Peter Akerlund as acting CFO
- Nov 14, 2022: Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.